Viewing nowCombinationOloduoetteok 20/10 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 202003972 · Approved 2020.05.28
Treatment of hypertension and dyslipidemia, inhibition of atherosclerotic progression and cardiovascular disease risk
This medication is used for patients who require combined administration of Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil is effective in controlling blood pressure in patients with essential hypertension. Rosuvastatin is used as an adjunct in patients with hypercholesterolemia and hyperlipidemia when not controlled by diet and exercise, and it especially lowers hypercholesterolemia, delaying the progression of atherosclerosis. Additionally, this medication helps reduce the risk of cardiovascular disease, thereby decreasing the risks associated with stroke, myocardial infarction, and arterial revascularization procedures. Therefore, this medication is used for the treatment of patients with concurrent hypertension and dyslipidemia.
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Safety and efficacy have not been established in children under 18 years of age.
This medication can cause serious harm or even death to the fetus and newborn if taken during the second and third trimesters of pregnancy. It must be discontinued immediately if pregnancy is confirmed, and women who may become pregnant should not take this medication. Individuals allergic to this medication or its components should not use it. Patients with severely impaired renal function, those undergoing dialysis, or those with severely compromised liver function should also not take this medication. This medication contains lactose, so patients with lactose intolerance or related genetic disorders should avoid it. Due to its blood pressure-lowering effects, dizziness or hypotension may occur, so caution is advised for patients taking high-dose diuretics or those with decreased blood volume. This medication may affect kidney function, so patients with kidney disease should frequently check their kidney function and electrolyte levels through blood tests. There is a risk of hyperkalemia, so serum potassium levels should be monitored regularly, especially in patients with heart or kidney disease. Symptoms such as muscle pain or weakness and, rarely, serious muscle damage (rhabdomyolysis) may occur, so immediate consultation with healthcare professionals is advised if muscle-related symptoms arise. This medication may affect liver function, so patients with liver disease should undergo regular liver function tests, and if symptoms of liver damage appear, discontinue use. Patients with a history of excessive alcohol consumption or liver disease should exercise caution when taking this medication. Dizziness may occur during activities requiring alertness such as driving or operating machinery, so caution is necessary. This medication may interact with other drugs, so it is essential to inform healthcare professionals of any other medications being taken. Pregnant or breastfeeding women should avoid taking this medication, as it may pose risks to the fetus during pregnancy. The safety and efficacy of this medication in children under 18 years of age have not been established. Elderly patients may require dosage adjustments, and in cases of overdose, symptoms such as hypotension and palpitations may occur, requiring immediate treatment. This medication should be kept out of the reach of children and should not be transferred to other containers.
Elevated ALT, elevated AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory disturbance, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, vascular edema, anaphylaxis, vomiting, chronic malabsorption syndrome, bowel vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, elevated blood pressure, back pain, increased blood creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including vascular edema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is safe to store at room temperature between 1 degree and 30 degrees Celsius.
White or pale yellow round film-coated tablets
30 tablets/box [10 tablets/Alu-Alu*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.